Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice

Anti-CD3 antibodies for type 1 diabetes: beyond expectations

(2011) Jean-François Bach   LANCET

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

(2011) Diane K Wherrett et al.   LANCET

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

(2011) Tom L. Van Belle et al.   PHYSIOLOGICAL REVIEWS

Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group

(2010) J. B. Matthews et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential

(2010) M. Peakman et al.   DIABETES

Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial

(2010) J. Ludvigsson et al.   DIABETOLOGIA

Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?

(2010) Xunrong Luo et al.   IMMUNITY

Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice

(2010) Devangi S. Mehta et al.   IMMUNOLOGY

Immunotherapy of type 1 diabetes — How to rationally prioritize combination therapies in T1D

(2010) Tobias Boettler et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Modulation of Gut-Associated Lymphoid Tissue Functions with Genetically ModifiedLactococcus lactis

(2010) Pieter Rottiers et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Genetics, pathogenesis and clinical interventions in type 1 diabetes

(2010) Jeffrey A. Bluestone et al.   NATURE

Actobiotics™ as a Novel Method for Cytokine Delivery

(2009) Lothar Steidler et al.   Annals of the New York Academy of Sciences

Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients

(2009) B. Keymeulen et al.   BLOOD

Induction of Antigen-Specific Tolerance by Oral Administration of Lactococcus lactis Delivered Immunodominant DQ8-Restricted Gliadin Peptide in Sensitized Nonobese Diabetic Ab  Dq8 Transgenic Mice

(2009) I. L. Huibregtse et al.   JOURNAL OF IMMUNOLOGY

Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis

(2009) Masako Murai et al.   NATURE IMMUNOLOGY

Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study

(2008) S. L. Thrower et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Innate immunity and intestinal microbiota in the development of Type 1 diabetes

(2008) Li Wen et al.   NATURE